Mafalda van Zeller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mafalda van Zeller has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Marta Drummond
Sleep and Ventilation Unit, Centro Hospitalar Universitário de São João and Faculty of Medicine, University of Porto, Porto, Portugal, Porto, Portugal
8 shared publicationsCarolina Lombardi
Sleep Medicine Center, Department of Cardiovascular, Neural and Metabolic Sciences, St Luke Hospital, Istituto Auxologico IRCCS, Milan, Italy. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy., Milan, Italy
2 shared publicationsJan Hedner
Department of Sleep Medicine, Sahlgrenska University Hospital, and the Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
2 shared publications- Ludger Grote
Department of Sleep Medicine, Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden
2 shared publications - Maria Rosaria Bonsignore
PROMISE Department University of Palermo Palermo Italy
2 shared publications - Marta Drummond
Centro de Responsabilidade Integrada Do Sono E Ventilação, Unidade Local de Saúde de São João, Alameda Prof. Hernâni Monteiro, Porto, Portugal
2 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA337
Gender Differences in OSA-COPD overlap syndrome: data from the European Sleep Apnoea Database
Introduction: The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) —known as overlap syndrome (OVS)—carries a greater risk of morbidity and mortality than either condition alone. However, the effect of sex on OVS clinical and measured features remains unclear. Aim: To analyse gender-differences in OVS (AHI≥5 plus a COPD diagnosis corroborated with FEV1/FVC < 0.7) in the European Sleep Apnoea Database (ESADA). Methods: This cross-sectional analysis included 1,527 patients with AHI≥5 [Women: 220 (76 OVS and 144 OSA); Men: 1307 (433 OVS and 874 OSA)]. Symptoms, comorbidities, and PSG data were compared between sexes, and the interaction of sex and COPD diagnosis was evaluated. Results: There were no gender differences in ESS score nor FEV1 in both OVS and OSA. Women presented significantly higher prevalence of insomnia symptoms (OVS: 7.9% vs. 1.8%; OSA: 11% vs. 3%) and lower AHI (OVS: 31 vs. 42 events/h; OSA: 32 vs. 42 events/h) compared to men in both OVS and OSA. Sleep efficiency showed clinically relevant sex-by-COPD interaction effects (Cohen’s d = 0.41 [95% CI: 0.08, 0.77]). Women had higher sleep efficiency in OSA and lower in OVS. Gender differences were not apparent on the prevalence of systemic hypertension (64% vs. 58%) (OR = 1.34 [0.81–2.23], p = 0.3), diabetes mellitus (34% vs.24%) ((OR = 1.62 [95% CI: 0.96–2.74], p = 0.091)) nor atrial fibrillation (6.7% vs.5.9%) ((OR = 1.14 [95% CI: 0.42–3.09], p = 0.8) in the OVS group, in contrast to OSA patients where those comorbidities were significantly more prevalent in women. Conclusion: Our data highlight the significance of sex-specific differences in both OVS and OSA patients, that while distinct, underscore the need for a more individualised approach.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA337
Gender Differences in OSA-COPD overlap syndrome: data from the European Sleep Apnoea Database
Introduction: The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) —known as overlap syndrome (OVS)—carries a greater risk of morbidity and mortality than either condition alone. However, the effect of sex on OVS clinical and measured features remains unclear. Aim: To analyse gender-differences in OVS (AHI≥5 plus a COPD diagnosis corroborated with FEV1/FVC < 0.7) in the European Sleep Apnoea Database (ESADA). Methods: This cross-sectional analysis included 1,527 patients with AHI≥5 [Women: 220 (76 OVS and 144 OSA); Men: 1307 (433 OVS and 874 OSA)]. Symptoms, comorbidities, and PSG data were compared between sexes, and the interaction of sex and COPD diagnosis was evaluated. Results: There were no gender differences in ESS score nor FEV1 in both OVS and OSA. Women presented significantly higher prevalence of insomnia symptoms (OVS: 7.9% vs. 1.8%; OSA: 11% vs. 3%) and lower AHI (OVS: 31 vs. 42 events/h; OSA: 32 vs. 42 events/h) compared to men in both OVS and OSA. Sleep efficiency showed clinically relevant sex-by-COPD interaction effects (Cohen’s d = 0.41 [95% CI: 0.08, 0.77]). Women had higher sleep efficiency in OSA and lower in OVS. Gender differences were not apparent on the prevalence of systemic hypertension (64% vs. 58%) (OR = 1.34 [0.81–2.23], p = 0.3), diabetes mellitus (34% vs.24%) ((OR = 1.62 [95% CI: 0.96–2.74], p = 0.091)) nor atrial fibrillation (6.7% vs.5.9%) ((OR = 1.14 [95% CI: 0.42–3.09], p = 0.8) in the OVS group, in contrast to OSA patients where those comorbidities were significantly more prevalent in women. Conclusion: Our data highlight the significance of sex-specific differences in both OVS and OSA patients, that while distinct, underscore the need for a more individualised approach.
- Open Access
- 22 December 2025
- Published by Taylor & Francis in Pulmonology
- Vol. 31 (1) , 2598915
Home mechanical ventilation in adults: Clinical practice recommendations from the Portuguese Respiratory Society home mechanical ventilation assembly
Background: The use of home mechanical ventilation (HMV) has been increasing worldwide, driven by widening of clinical applications and improved patient survival rates. In Portugal, recent data indicate an even faster growth, although national HMV recommendations have remained unchanged for 25 years. Research question: We aimed to provide an update in clinical practice guidelines for HMV in adults, applicable to the Portuguese context, grounded on the latest available evidence and experts' opinion. Study design and methods: A multidisciplinary panel with experience in HMV in the adult population was assembled. A comprehensive literature search was conducted during March 2023 regarding specific topics: equipment, ventilatory modes and interfaces, HMV initiation, follow-up and monitoring, disease specificities (neuromuscular diseases, obesity-hypoventilation syndrome, restrictive chest wall diseases; chronic obstructive pulmonary disease, and other diseases), home mechanical invasive ventilation, and palliative and end of life care. A 2-round Delphi process was conducted to establish consensus among panel members. A minimum agreement threshold of 80% was required. Results: Out of 88 recommendations initially included in the Delphi process, 61 were selected by consensus. Conclusion: Final recommendations grounded in the current level of evidence are outlined, and the key limitations and proposals for future research are discussed.
- 22 December 2025
- Published by Taylor & Francis in Pulmonology
- Vol. 31 (1) , 2598915
Open AccessHome mechanical ventilation in adults: Clinical practice recommendations from the Portuguese Respiratory Society home mechanical ventilation assembly
Background: The use of home mechanical ventilation (HMV) has been increasing worldwide, driven by widening of clinical applications and improved patient survival rates. In Portugal, recent data indicate an even faster growth, although national HMV recommendations have remained unchanged for 25 years. Research question: We aimed to provide an update in clinical practice guidelines for HMV in adults, applicable to the Portuguese context, grounded on the latest available evidence and experts' opinion. Study design and methods: A multidisciplinary panel with experience in HMV in the adult population was assembled. A comprehensive literature search was conducted during March 2023 regarding specific topics: equipment, ventilatory modes and interfaces, HMV initiation, follow-up and monitoring, disease specificities (neuromuscular diseases, obesity-hypoventilation syndrome, restrictive chest wall diseases; chronic obstructive pulmonary disease, and other diseases), home mechanical invasive ventilation, and palliative and end of life care. A 2-round Delphi process was conducted to establish consensus among panel members. A minimum agreement threshold of 80% was required. Results: Out of 88 recommendations initially included in the Delphi process, 61 were selected by consensus. Conclusion: Final recommendations grounded in the current level of evidence are outlined, and the key limitations and proposals for future research are discussed.
- Open Access
- 2 June 2024
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 18 (6) , 369-379
Sleep disordered breathing: OSA-COPD overlap
Sleep has important effects on breathing and gas exchange that may have negative consequences in patients with chronic obstructive pulmonary disease (COPD). COPD and obstructive sleep apnea (OSA) are highly prevalent and may coexist, which is referred to as the overlap syndrome. The probability of OSA-COPD overlap represents the balance of protective and promoting factors such as hyperinflation and fluid retention; thus, different clinical COPD phenotypes influence the likelihood of comorbid OSA. The clinical presentation of OSA-COPD overlap is nonspecific, and the diagnosis requires clinical awareness to identify patients needing overnight studies. Both COPD and OSA are associated with a range of overlapping physiological and biological disturbances including hypoxia and inflammation that contribute to cardiovascular comorbidities. The management of OSA-COPD overlap patients differs from those with COPD alone and the survival of overlap patients treated with positive airway pressure (PAP) is superior to those untreated. The recognition of OSA-COPD overlap has important clinical relevance because of its impact on outcomes and management. Management of the overlap should address both sleep quality and disordered gas exchange. PAP therapy has demonstrated reductions in COPD exacerbations, hospitalizations, healthcare costs and mortality in overlap patients.
- 2 June 2024
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 18 (6) , 369-379
Open AccessSleep disordered breathing: OSA-COPD overlap
Sleep has important effects on breathing and gas exchange that may have negative consequences in patients with chronic obstructive pulmonary disease (COPD). COPD and obstructive sleep apnea (OSA) are highly prevalent and may coexist, which is referred to as the overlap syndrome. The probability of OSA-COPD overlap represents the balance of protective and promoting factors such as hyperinflation and fluid retention; thus, different clinical COPD phenotypes influence the likelihood of comorbid OSA. The clinical presentation of OSA-COPD overlap is nonspecific, and the diagnosis requires clinical awareness to identify patients needing overnight studies. Both COPD and OSA are associated with a range of overlapping physiological and biological disturbances including hypoxia and inflammation that contribute to cardiovascular comorbidities. The management of OSA-COPD overlap patients differs from those with COPD alone and the survival of overlap patients treated with positive airway pressure (PAP) is superior to those untreated. The recognition of OSA-COPD overlap has important clinical relevance because of its impact on outcomes and management. Management of the overlap should address both sleep quality and disordered gas exchange. PAP therapy has demonstrated reductions in COPD exacerbations, hospitalizations, healthcare costs and mortality in overlap patients.
- Open Access
- 6 April 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Sleep and cardiometabolic comorbidities in the obstructive sleep apnoea–COPD overlap syndrome: data from the European Sleep Apnoea Database
Aim: The impact of obstructive sleep apnoea (OSA)–COPD overlap syndrome (OVS) on sleep quality and cardiovascular outcomes has not been fully explored. We aimed to compare clinical and polysomnographic characteristics of patients with OVSversuspatients with OSA, and to explore pathophysiological links between OVS and comorbidities.Study design and methods: This cross-sectional analysis initially included data from 5600 patients with OSA and lung function in the European Sleep Apnoea Database. Two subgroups of patients with OSA (n=1018) or OVS (n=509) were matched (2:1) based on sex, age, body mass index and apnoea–hypopnea index at baseline.Results: After matching, patients with OVS had more severe hypoxia, lower sleep efficiency and presented with higher prevalences of arterial hypertension, ischaemic heart disease and heart failure compared with patients with OSA. OVS was associated with a significant decrease in sleep efficiency (mean difference (β) −3.0%, 95% CI −4.7 to −1.3) and in nocturnal mean peripheral oxyhaemoglobin saturation (SpO2) (β −1.1%, 95% CI −1.5 to −0.7). Further analysis revealed that a decrease in forced expiratory volume in 1 s and arterial oxygen tension was related to a decrease in sleep efficiency and in mean nocturnalSpO2. A COPD diagnosis increased the odds of having heart failure by 1.75 (95% CI 1.15–2.67) and systemic hypertension by 1.36 (95% CI 1.07–1.73). Nocturnal hypoxia was strongly associated with comorbidities; the mean nocturnalSpO2and T90 (increase in time belowSpO2of 90%) were associated with increased odds of systemic hypertension, diabetes and heart failure but the oxygen desaturation index was only related to hypertension and diabetes.Conclusion: Patients with OVS presented with more sleep-related hypoxia, a reduced sleep quality and a higher risk for heart failure and hypertension.
- 6 April 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Open AccessSleep and cardiometabolic comorbidities in the obstructive sleep apnoea–COPD overlap syndrome: data from the European Sleep Apnoea Database
Aim: The impact of obstructive sleep apnoea (OSA)–COPD overlap syndrome (OVS) on sleep quality and cardiovascular outcomes has not been fully explored. We aimed to compare clinical and polysomnographic characteristics of patients with OVSversuspatients with OSA, and to explore pathophysiological links between OVS and comorbidities.Study design and methods: This cross-sectional analysis initially included data from 5600 patients with OSA and lung function in the European Sleep Apnoea Database. Two subgroups of patients with OSA (n=1018) or OVS (n=509) were matched (2:1) based on sex, age, body mass index and apnoea–hypopnea index at baseline.Results: After matching, patients with OVS had more severe hypoxia, lower sleep efficiency and presented with higher prevalences of arterial hypertension, ischaemic heart disease and heart failure compared with patients with OSA. OVS was associated with a significant decrease in sleep efficiency (mean difference (β) −3.0%, 95% CI −4.7 to −1.3) and in nocturnal mean peripheral oxyhaemoglobin saturation (SpO2) (β −1.1%, 95% CI −1.5 to −0.7). Further analysis revealed that a decrease in forced expiratory volume in 1 s and arterial oxygen tension was related to a decrease in sleep efficiency and in mean nocturnalSpO2. A COPD diagnosis increased the odds of having heart failure by 1.75 (95% CI 1.15–2.67) and systemic hypertension by 1.36 (95% CI 1.07–1.73). Nocturnal hypoxia was strongly associated with comorbidities; the mean nocturnalSpO2and T90 (increase in time belowSpO2of 90%) were associated with increased odds of systemic hypertension, diabetes and heart failure but the oxygen desaturation index was only related to hypertension and diabetes.Conclusion: Patients with OVS presented with more sleep-related hypoxia, a reduced sleep quality and a higher risk for heart failure and hypertension.
- Open Access
- 26 January 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Clinical characteristics and positive airway pressure adherence among elderly European sleep apnoea patients from the ESADA cohort
Background: The prevalence of obstructive sleep apnoea (OSA) is growing as the population is ageing. However, data on the clinical characteristics of elderly patients with OSA and their adherence to positive airway pressure (PAP) treatment are scarce.Methods: Data from 23 418 30–79-year-old OSA patients prospectively collected into the ESADA database during 2007–2019 were analysed. Information on PAP use (h·day−1) in association with a first follow-up visit was available for 6547 patients. The data was analysed according to 10-year age groups.Results: The oldest age group was less obese, less sleepy and had a lower apnoea–hypopnoea index (AHI) compared with middle-aged patients. The insomnia phenotype of OSA was more prevalent in the oldest age group than in the middle-aged group (36%, 95% CI 34–38versus26%, 95% CI 24–27, p−1(95% CI 5.44–5.75). PAP adherence did not differ between clinical phenotypes based on subjective daytime sleepiness and sleep complaints suggestive of insomnia in the oldest age group. A higher score on the Clinical Global Impression Severity (CGI-S) scale predicted poorer PAP adherence.Conclusion: The elderly patient group was less obese, less sleepy, had more insomnia symptoms and less severe OSA, but were rated to be more ill compared with the middle-aged patients. Elderly patients with OSA adhered to PAP therapy equally well as middle-aged patients. Low global functioning (measured by CGI-S) in the elderly patient predicted poorer PAP adherence.
- 26 January 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Open AccessClinical characteristics and positive airway pressure adherence among elderly European sleep apnoea patients from the ESADA cohort
Background: The prevalence of obstructive sleep apnoea (OSA) is growing as the population is ageing. However, data on the clinical characteristics of elderly patients with OSA and their adherence to positive airway pressure (PAP) treatment are scarce.Methods: Data from 23 418 30–79-year-old OSA patients prospectively collected into the ESADA database during 2007–2019 were analysed. Information on PAP use (h·day−1) in association with a first follow-up visit was available for 6547 patients. The data was analysed according to 10-year age groups.Results: The oldest age group was less obese, less sleepy and had a lower apnoea–hypopnoea index (AHI) compared with middle-aged patients. The insomnia phenotype of OSA was more prevalent in the oldest age group than in the middle-aged group (36%, 95% CI 34–38versus26%, 95% CI 24–27, p−1(95% CI 5.44–5.75). PAP adherence did not differ between clinical phenotypes based on subjective daytime sleepiness and sleep complaints suggestive of insomnia in the oldest age group. A higher score on the Clinical Global Impression Severity (CGI-S) scale predicted poorer PAP adherence.Conclusion: The elderly patient group was less obese, less sleepy, had more insomnia symptoms and less severe OSA, but were rated to be more ill compared with the middle-aged patients. Elderly patients with OSA adhered to PAP therapy equally well as middle-aged patients. Low global functioning (measured by CGI-S) in the elderly patient predicted poorer PAP adherence.
- 1 October 2021
- Published by Elsevier in Sleep Medicine
- Vol. 86, 123
Phone medical appointments for sleep-disordered breathing in Covid-19 pandemic – were they useful?
- 1 October 2021
- Published by Elsevier in Sleep Medicine
- Vol. 86, 123
Phone medical appointments for sleep-disordered breathing in Covid-19 pandemic – were they useful?
- Open Access
- 1 April 2021
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 91 (3)
Non-invasive ventilation in the elderly – never too late!
Dear Editor, Practising evidence-based medicine in an ageing population is challenging. Nevertheless, using age as a diagnostic or therapeutic procedure contraindication is less and less common. Domiciliary non-invasive ventilation (NIV) in chronic respiratory failure patients has been largely used; however, data from older people is scarce...
- 1 April 2021
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 91 (3)
Open AccessNon-invasive ventilation in the elderly – never too late!
Dear Editor, Practising evidence-based medicine in an ageing population is challenging. Nevertheless, using age as a diagnostic or therapeutic procedure contraindication is less and less common. Domiciliary non-invasive ventilation (NIV) in chronic respiratory failure patients has been largely used; however, data from older people is scarce...
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , OA5180
Impact of PAP in reducing cardiovascular events in OSA patients: a 10-years follow-up
Introduction: Obstructive sleep apnea (OSA) has gained a huge relevance, mainly due to its proven impact in multiple cardiovascular (CV) events. Accumulating evidence suggests that successful OSA treatment with positive airway pressure (PAP) can improve CV outcomes. Aim: This study aimed to evaluate the incidence of CV and CeV events and related mortality in 89 males with moderate-to-severe OSA treated with PAP over 10 years, and to assess its relation with PAP adherence. Results: Of 89 patients included (mean age 53.5±11.7 years, BMI=33.2±4.9 kg/m2, initial AHI=52.9±20.6 events/h, Epworth scale=12.2±5.3), 17 were active smokers, 63 had hypertension, 1 hyperuricemia, and 5 had previous CV/CeV events. Over follow-up, AHI and Epworth scale decreased significantly (p<0.001) reaching minimum levels of 2.6±1.8 events/h and 4.2±3.9, respectively. Most of patients were PAP adherent (mean objective compliance: 93.8±13.9%, with 6.5±1.6 h/use/day). At time of last evaluation, mean adherence rate and hours use/day were, respectively, 98.1±3.1% and 7.0±1.4, being found a progressively strong negative correlation between PAP adherence and CeV/CV events, mostly after the 6th year. Over this period, 9 patients had CV and 5 CeV events, and 2 experienced both events. Mean survival time was 123.9±25.9 months: lower in those who had CV and/or CeV events (p<0.001). Ten patients died (3 by CVD complication, 1 myocardial infarction, 2 stroke, and 1 cardiopulmonary arrest). Conclusions: Although AHI presented an immediate and sustained decrease with PAP treatment, only an effective PAP adherence (especially after 24 months) seems to be effective in decreasing CV/CeV events, especially when used for more than 6 years.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , OA5180
Impact of PAP in reducing cardiovascular events in OSA patients: a 10-years follow-up
Introduction: Obstructive sleep apnea (OSA) has gained a huge relevance, mainly due to its proven impact in multiple cardiovascular (CV) events. Accumulating evidence suggests that successful OSA treatment with positive airway pressure (PAP) can improve CV outcomes. Aim: This study aimed to evaluate the incidence of CV and CeV events and related mortality in 89 males with moderate-to-severe OSA treated with PAP over 10 years, and to assess its relation with PAP adherence. Results: Of 89 patients included (mean age 53.5±11.7 years, BMI=33.2±4.9 kg/m2, initial AHI=52.9±20.6 events/h, Epworth scale=12.2±5.3), 17 were active smokers, 63 had hypertension, 1 hyperuricemia, and 5 had previous CV/CeV events. Over follow-up, AHI and Epworth scale decreased significantly (p<0.001) reaching minimum levels of 2.6±1.8 events/h and 4.2±3.9, respectively. Most of patients were PAP adherent (mean objective compliance: 93.8±13.9%, with 6.5±1.6 h/use/day). At time of last evaluation, mean adherence rate and hours use/day were, respectively, 98.1±3.1% and 7.0±1.4, being found a progressively strong negative correlation between PAP adherence and CeV/CV events, mostly after the 6th year. Over this period, 9 patients had CV and 5 CeV events, and 2 experienced both events. Mean survival time was 123.9±25.9 months: lower in those who had CV and/or CeV events (p<0.001). Ten patients died (3 by CVD complication, 1 myocardial infarction, 2 stroke, and 1 cardiopulmonary arrest). Conclusions: Although AHI presented an immediate and sustained decrease with PAP treatment, only an effective PAP adherence (especially after 24 months) seems to be effective in decreasing CV/CeV events, especially when used for more than 6 years.
- 11 April 2019
- Published by European Respiratory Society (ERS)
- Vol. 5 (suppl 3) , P59
Looking inside sleep specialized consultations: are other doctors prescribing as the experts do?
Obstructive sleep apnea (OSA) is a chronic disease with raising prevalence and important morbimortality, driving the need of sleep expert consultations. Nonetheless, many patients are observed by general pulmonologists whose medical conduct may differ from the experts. The aim of this study was to compare the conduct applied by sleep specialists, general pulmonologists and pulmonology residents in OSA patients from the Sleep Laboratory Unit, Hospital São João, Porto – Portugal. From 190 patients included (mean age 56.2±12.2years), 39.1% had mild OSA, 24.4% moderate, 26.1% severe. Mean AHI=21.7±18.7/h, desaturation index=20.8±18.0, Epworth scale=9.6±6.0, daytime pCO2=41.2±12.9 mmHg. For clinical decisions, IAH was the most valued criteria by residents (44.2%) and pulmonologists (30%), (Cohen kappa coefficient=0.156; p<0.001). APAP/CPAP was mostly prescribed by pulmonologists (45.9%, kappa=0.495), followed by residents (46.0%, kappa=0.642) and sleep specialists (39.5%). Residents prescribed more CPAP (8%) then specialists (0.5%) and pulmonologists (0%). BiPAP was more often the first option of pulmonologist (4.7%, kappa=0.370), followed by residents (3.1%, kappa=0.442) and sleep specialist (0.5%). These findings pointed out that sleep specialists are more conservative when prescribing OSA therapy, saving costs but probably valuing other PSG criteria besides AHI. Further studies are needed to understand the best way to manage these patients – conservative versus defensive medicine.
- 11 April 2019
- Published by European Respiratory Society (ERS)
- Vol. 5 (suppl 3) , P59
Looking inside sleep specialized consultations: are other doctors prescribing as the experts do?
Obstructive sleep apnea (OSA) is a chronic disease with raising prevalence and important morbimortality, driving the need of sleep expert consultations. Nonetheless, many patients are observed by general pulmonologists whose medical conduct may differ from the experts. The aim of this study was to compare the conduct applied by sleep specialists, general pulmonologists and pulmonology residents in OSA patients from the Sleep Laboratory Unit, Hospital São João, Porto – Portugal. From 190 patients included (mean age 56.2±12.2years), 39.1% had mild OSA, 24.4% moderate, 26.1% severe. Mean AHI=21.7±18.7/h, desaturation index=20.8±18.0, Epworth scale=9.6±6.0, daytime pCO2=41.2±12.9 mmHg. For clinical decisions, IAH was the most valued criteria by residents (44.2%) and pulmonologists (30%), (Cohen kappa coefficient=0.156; p<0.001). APAP/CPAP was mostly prescribed by pulmonologists (45.9%, kappa=0.495), followed by residents (46.0%, kappa=0.642) and sleep specialists (39.5%). Residents prescribed more CPAP (8%) then specialists (0.5%) and pulmonologists (0%). BiPAP was more often the first option of pulmonologist (4.7%, kappa=0.370), followed by residents (3.1%, kappa=0.442) and sleep specialist (0.5%). These findings pointed out that sleep specialists are more conservative when prescribing OSA therapy, saving costs but probably valuing other PSG criteria besides AHI. Further studies are needed to understand the best way to manage these patients – conservative versus defensive medicine.
- Open Access
- 31 August 2018
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 14 (3) , 248-249
Pneumology and sleep disordered breathing training in Portugal
In Portugal, a medical degree takes 6 years, including a master's degree, ever since the Bologna Agreement of 2009. After this, and according to the Ordem dos Médicos (College of Physicians), one must complete 2 years of fully supervised clinical practice to be able to practice medicine. During this period, junior doctors rotate through several different medical and chirurgical specialties, after which and according to their grade on a national examination, they chose a specialty and location. Pneumology/respiratory medicine is one of the options and every year roughly 30 residents begin this 5-year specialty. Junior doctors usually choose where to perform their residency according to the subspecialties available in a particular hospital, their relationship with academia, opportunities for research projects and to go abroad, among other factors.
- 31 August 2018
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 14 (3) , 248-249
Open AccessPneumology and sleep disordered breathing training in Portugal
In Portugal, a medical degree takes 6 years, including a master's degree, ever since the Bologna Agreement of 2009. After this, and according to the Ordem dos Médicos (College of Physicians), one must complete 2 years of fully supervised clinical practice to be able to practice medicine. During this period, junior doctors rotate through several different medical and chirurgical specialties, after which and according to their grade on a national examination, they chose a specialty and location. Pneumology/respiratory medicine is one of the options and every year roughly 30 residents begin this 5-year specialty. Junior doctors usually choose where to perform their residency according to the subspecialties available in a particular hospital, their relationship with academia, opportunities for research projects and to go abroad, among other factors.